Sizzling Stock Picks

[StockDetective]

$ARYC heavy accumulation...

Recent press releases:

5-19-18: Sunnyvale, May 09, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces receipt of a new clinical licensure from the Centers for Medicare and Medicaid Services (CMS), which oversees the Clinical Laboratory Improvement Amendments (CLIA) Program. Arrayit's new CLIA license, issued in conjunction with the Department of Health and Human Services (HHS) and the California Department of Public Health (CDPH), provides certification for its Silicon Valley clinical laboratory.
https://www.marketwatch.com/story/arrayit-corporation-announces-new-clinical-licensure-from-the-centers-for-medicare-and-medicaid-services-2018-05-09?siteid=bigcharts&dist=bigcharts

5-21-18: Arrayit Corporation Scores 100% on Proficiency Testing Conducted by the College of American Pathologists as clinical team aces CAP PT in highly quantitative measurements of IgE using a blinded study protocol. Congratulations to our amazing clinical team!
http://www.globenewswire.com/news-release/2018/05/16/1507332/0/en/Arrayit-Corporation-Scores-100-on-Proficiency-Testing-Conducted-by-the-College-of-American-Pathologists.html

5-30-18: Sunnyvale, CA , May 30, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has achieved the clinical testing accuracy required for reimbursement under Medicare and Medicaid. Accuracy testing, supervised by the College of American Pathologists (CAP), assesses quantitative measurements of the immunoglobulin E (IgE) regulated analyte in the general immunology proficiency testing program. Arrayit’s testing performance included a score of 100% on the SA-2018 proficiency event and constituted successful cumulative performance required by the Centers for Medicare and Medicaid Services (CMS) over a one-year testing period. CMS regulates approximately 260,000 clinical laboratories through the Clinical Laboratory Improvement Amendments (CLIA) program, and proper certification is required to receive Medicare and Medicaid payments.
https://www.marketwatch.com/story/arrayit-corporation-achieves-testing-accuracy-required-for-medicare-and-medicaid-reimbursement-2018-05-30?siteid=bigcharts&dist=bigcharts

6-18-18: June 18, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has engaged a nationwide network of professional sales representatives ("sales reps") to sell and distribute the company's allergy tests across the Continental United States, with focus areas in the Pacific Northwest, West, Southwest, Rocky Mountain, Midwest, Northeast and Southeast regions. The network comprises 1,700 sales professionals including 500 sales reps with specific training in finger stick sampling, blood card collection and microarray technology. This extensive professional network will be used to enroll hospitals, health maintenance organizations (HMOs), doctor's and dentist's offices, health clinics and retail stores into the allergy-testing program.
https://www.marketwatch.com/story/arrayit-corporation-announces-nationwide-allergy-testing-sales-and-distribution-network-2018-06-18?siteid=bigcharts&dist=bigcharts

6-29-18: Arrayit signs capital financing agreement with a top buy-side analyst at a leading corporate intelligence firm headquartered in London UK with offices in New York and providing buy-side intelligence to high net worth retail investors, institutional investors and hedge funds.
https://twitter.com/arrayit/status/1012723616373280768

7-2-18: Sunnyvale, July 02, 2018 (GLOBE NEWSWIRE) -- July 2, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has completed an allergy testing pilot program for one of nation’s largest chains of retail stores. The retailer collected finger stick blood specimens from 126 customers at their in-store clinics, and shipped the blood cards to Arrayit for processing. Arrayit processed the specimens and reported 126 quantitative total immunoglobulin E (IgE) measurements and 15,120 allergen-specific determinations indicative of food and environmental allergies. The test results were reviewed and approved by the retail chain’s Chief Medical Officer.
https://www.marketwatch.com/story/arrayit-corporation-completes-allergy-testing-pilot-program-for-one-of-the-nations-largest-retail-chains-2018-07-02?siteid=bigcharts&dist=bigcharts

7-3-18: Arrayit senior management receives NASDAQ and NYSE up-listing proposal from small and mid-cap consulting experts http://uplisting.com focusing on growth companies seeking to improve and enhance shareholder value by listing on a major stock exchange http://www.uplisting.com
https://twitter.com/arrayit/status/1014187818891935744
7-3-18: Arrayit provides 7/2/18 FDA update: (1) excellent meeting, (2) large attendance by FDA top brass, (3) insightful and instructive, (4) our entire clinical team wishes to thank the agency for their feedback and generosity, and (5) we believe that our test will receive FDA approval.
https://twitter.com/arrayit/status/1014171600051007488
7-8-18: Arrayit web design team updates investor main page and 33 sub-pages including updated information and links regarding Arrayit technology, auditors, biochemistry 101, celebrity spokesperson, CEO, SEC filings, XBRL filings and many other ARYC investor topics http://arrayit.com/Microarray_Investor/microarray_investor.html …
https://twitter.com/arrayit/status/1016023938470576128
7-16-18: July 16, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces the sale of clinical instrumentation to the United States Food and Drug Administration (FDA). Arrayit uses the same clinical instrumentation in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH). The instrumentation reads and reports test results for the company's allergy and dietary wellness tests and pipeline tests for ovarian cancer and Parkinson's Disease (PD).
https://www.marketwatch.com/press-release/arrayit-corporation-reports-clinical-instrumentation-sale-to-the-united-states-food-and-drug-administration-2018-07-16?siteid=bigcharts&dist=bigcharts

7-25-18: Arrayit senior management completes analyst call with top buy side analyst at the prestigious Alpha Deal Group headquartered in New York NY USA and providing premium independent due diligence for high net-worth retail, instituional and hedge fund customers (link: http://www.alphadealgroup.com) alphadealgroup.com
https://twitter.com/arrayit/status/1022158461302267905

7-30-18: Sunnyvale, July 30, 2018 (GLOBE NEWSWIRE) -- July 30, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, signs allergy testing contracts with a consortium of medical clinics nationwide. The network comprises 178 medical clinics in 29 of the 48 contiguous United States including the Northeast, Southeast, Midwest, South, Southwest, Pacific and Pacific Northwest regions, with single clinics staffing up to 70 physicians. The clinics are using Arrayit allergy testing services to assist physicians in diagnosing and treating allergy and asthma across a wide range of medical specialties and focus areas including anti-aging, back pain and sciatica, chiropractic care, dermatology, digestive health, ear nose and throat (ENT), family medicine, gastroenterology, health and beauty, immunology, integrative medicine, internal medicine, obesity, obstetrics and gynecology (OB-GYN), pain relief, pediatrics, personalized medicine, preventative medicine, primary care, rehabilitation, sinus, spinal care, urgent care, weight loss, wellness and women’s health.
Arrayit recently established a nationwide sales network of 1,700 sales professionals to sell and distribute the company’s finger stick microarray tests to medical clinics and retail chains, completed allergy pilot testing with one the nation’s largest chains of retail stores, met with top officials at the United States Food and Drug Administration (FDA) to discuss FDA approval of a major product line, and reported the sale of clinical instrumentation to the FDA. Arrayit microarray tests conveniently use a few drops of patient blood collected on a blood card to assist doctors in identifying and treating food intolerance, allergy and asthma, and pipeline indications for more serious conditions such as ovarian cancer and Parkinson’s Disease. Doctors can use allergy test results as quantitative tools to inform decisions regarding allergy medicines, immunotherapy, food elimination and lifestyle changes.
https://www.marketwatch.com/press-release/arrayit-corporation-signs-allergy-testing-contracts-with-a-nationwide-consortium-of-medical-clinics-2018-07-30?siteid=bigcharts&dist=bigcharts

8-7-18: Arrayit senior management submits $5,000,000 strategic investment proposal to a companion diagnostics and therapeutics leader headquartered in the San Francisco Bay Area USA and commercializing medicines for the massive $45 billion neurodegenerative market
https://twitter.com/arrayit/status/1026860386782339072

8-13-18: August 13, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, has been approved for in-store allergy testing promotions by a major United States retailer. Arrayit sales and marketing experts will conduct allergy test promotions in-store, and medical professionals at in-store clinics will collect finger stick blood specimens. Two thousand retail locations nationwide averaging 3,000 customer visits per store per day would give Arrayit access to 6 million retail customers daily, creating the potential for exponential sales growth. This promotional campaign required rigorous vetting and high-level corporate approval by the retailer, which reports revenues exceeding $50 billion annually.

https://www.marketwatch.com/press-release/arrayit-corporation-receives-approval-for-in-store-promotions-by-a-major-retail-chain-2018-08-13?siteid=bigcharts&dist=bigcharts

8-27-18: August 27, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces allergy testing partnerships with multiple providers of allergen immunotherapy products including sub-cutaneous, sublingual, and oral allergy medicines designed to treat patients of allergy and asthma. Allergen immunotherapy, a time-tested clinical approach, can reduce or eliminate allergy and asthma symptoms by lowering the levels of specific cellular proteins known as immunoglobulin E (IgE) molecules that activate the immune system and trigger immune responses. Through these partnerships, doctors prescribing Arrayit allergy tests gain access to a portfolio of safe, effective and convenient allergy medicines for their allergy and asthma patients, including custom immunotherapy products formulated upon review of quantitative allergy test results.
https://www.marketwatch.com/press-release/arrayit-corporation-announces-allergy-testing-partnerships-with-major-allergy-therapeutics-providers-2018-08-27-51843016?siteid=bigcharts&dist=bigcharts
9-10-18: September 10, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that Arrayit's proprietary finger stick allergy microarray test has been approved for direct Medicare billing by the Centers for Medicare and Medicaid Services (CMS). The Medicare national health insurance program provides health insurance to more than 55 million Americans annually, including 46 million seniors and 9 million younger people. CMS projects a 2018 Medicare budget of approximately $705,000,000,000 ($705 billion dollars), representing about 17% of total federal spending.
https://www.marketwatch.com/press-release/arrayit-corporation-approved-for-direct-medicare-billing-by-the-centers-for-medicare-and-medicaid-services-2018-09-10?siteid=bigcharts&dist=bigcharts

Sunnyvale, Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that Arrayit’s proprietary finger stick allergy microarray test has been approved for direct Medicare billing by the Centers for Medicare and Medicaid Services (CMS). The Medicare national health insurance program provides health insurance to more than 55 million Americans annually, including 46 million seniors and 9 million younger people. CMS projects a 2018 Medicare budget of approximately $705,000,000,000 ($705 billion dollars), representing about 17% of total federal spending.

http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Approved_f/arrayit_corporation_approved_for_direct_medicare_billing_by_the_.html